DATATRAK's New Services Group Awarded Consulting Contract

DATATRAK's New Services Group Awarded Consulting Contract
October 5th, 2010 - Filed under: Press Releases.

CLEVELAND, [Oct 5] /PRNewswire-FirstCall/ - DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the award of a consulting contract with an existing global research-based biopharmaceutical client to provide clinical data management and trial design services. With the award of this contract, DATATRAK is expanding its staff to include experienced clinical data managers to provide services under the direction of Dr. Bill Gluck.

"The continued acceptance of the DATATRAK ONETM unified business model is gaining favor and allows us to deliver high impact results to specific and complex study challenges for our clients. Customers, prospects and even competitors are validating a unified approach of services and software as the future of Clinical Trial Management," said Laurence P. Birch, DATATRAK's Chairman and CEO. Mr. Birch continued, "DATATRAK is the only solution provider focused on reducing the customer's total trial costs through a combination of consulting services and the only truly unified software platform."

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONETM, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinicalTM software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 67 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the Pink OTC Markets on August 13, 2010 announcing its results for the three-month period ending June 30, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT:
Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.